The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients

Kidney International

Volumn 81, Issue 5, 2012, Pages 469-476

  Wetmore, James B ^a   Mahnken, Jonathan D ^a   Rigler, Sally K ^a   Ellerbeck, Edward F ^a   Mukhopadhyay, Purna ^a   Spertus, John A ^b,c   Hou, Qingjiang ^a   Shireman, Theresa I ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

atrial fibrillation; dialysis; end stage renal disease; prevalence

Indexed keywords

ADULT; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMODIALYSIS; HOSPITAL COST; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; UNITED STATES;

EID: 84857095835     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.416     Document Type: Article

References (40)

1. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
2. United States Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2005.
3. Abe S, Yoshizawa M, Nakanishi N et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 1996; 131: 1137-1144. (Pubitemid 26176992)
4. Vazquez E, Sanchez-Perales C, Borrego F et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140: 886-890.
5. Atar I, Konas D, Acikel S et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006; 106: 47-51. (Pubitemid 41728908)
6. Fabbian F, Catalano C, Lambertini D et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol 2000; 54: 234-239.
7. Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46: 897-902. (Pubitemid 41505464)
8. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-1106.
9. Korantzopoulos P, Kokkoris S, Liu T et al. Atrial fibrillation in end-stage renal disease. Pacing Clin Electrophysiol 2007; 30: 1391-1397. (Pubitemid 350063847)
10. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952. (Pubitemid 28446646)
11. Vazquez E, Sanchez-Perales C, Garcia-Garcia F et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76: 324-330.
12. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
13. Winkelmayer WC, Patrick AR, Liu J et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011; 22: 349-357.
14. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934. (Pubitemid 30005032)
15. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375. (Pubitemid 32424106)
16. Wetmore JB, Rigler SK, Mahnken JD et al. Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage? Nephrol Dial Transplant 2010; 25: 198-205.
17. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-2692. (Pubitemid 37475596)
18. Abbott KC, Trespalacios FC, Taylor AJ et al. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 2003; 4: 1.
19. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847. (Pubitemid 28213628)
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-2497.
21. Chambless LE, Folsom AR, Sharrett AR et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 2003; 56: 880-890. (Pubitemid 37162663)
22. Folsom AR, Chambless LE, Duncan BB et al. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003; 26: 2777-2784. (Pubitemid 37205546)
23. Schnabel RB, Sullivan LM, Levy D et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-745.
24. Chamberlain AM, Agarwal SK, Folsom AR et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011; 107: 85-91.
25. Kovesdy CP, Kalantar-Zadeh K. Introduction: the reverse epidemiology controversy. Semin Dial 2007; 20: 485.
26. Kalantar-Zadeh K. What is so bad about reverse epidemiology anyway? Semin Dial 2007; 20: 593-601.
27. Volkova N, McClellan W, Soucie JM et al. Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients. Nephrol Dial Transplant 2006; 21: 2202-2209. (Pubitemid 44295046)
28. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459. (Pubitemid 43673427)
29. Trivedi H, Xiang Q, Klein JP. Risk factors for non-fatal myocardial infarction cardiac death in incident dialysis patients. Nephrol Dial Transplant 2009; 24: 258-266.
30. Hirth RA, Turenne MN, Wheeler JR et al. Provider monitoring and pay-forperformance when multiple providers affect outcomes: an application to renal dialysis. Health Serv Res 2009; 44: 1585-1602.
31. Foley RN, Chen SC, Collins AJ. Hemodialysis access at initiation in the United States, 2005 to 2007: still "catheter first". Hemodial Int 2009; 13: 533-542.
32. Foley RN, Roberts TL, Liu J et al. Mortality from cancer among US hemodialysis patients, 1995-2005. Am J Nephrol 2010; 31: 518-526.
33. Dalrymple LS, Johansen KL, Chertow GM et al. Infection-related hospitalizations in older patients with ESRD. Am J Kidney Dis 2010; 56: 522-530.
34. Liu J, Huang Z, Gilbertson DT et al. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010; 77: 141-151.
35. Seliger SL. Comorbidity and confounding in end-stage renal disease. Kidney Int 2010; 77: 83-85.
36. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53. (Pubitemid 37046632)
37. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. (Pubitemid 32537350)
38. Seliger SL, Gillen DL, Longstreth Jr WT et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609. (Pubitemid 36871932)
39. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. (Pubitemid 37087616)
40. Boulanger L, Hauch O, Friedman M et al. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother 2006; 40: 1024-1029. (Pubitemid 43890902)